Genocea Biosciences Announces New Research Identifying Potential Vaccine Candidates for Chlamydia

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genocea Biosciences announced today the publication of a new study characterizing two protein antigens that may hold utility in the design of novel vaccines for Chlamydia trachomatis. The research, led by Jessica Baker Flechtner, Ph.D., Vice President of Research, appears in the current issue of Vaccine. The authors found that both antigens stimulated potent immune responses and long-lived protection against vaginal infection in preclinical models of Chlamydia, confirming the critical role that T cell responses can play in the control of this infection.